Open access
Sep 2026
Prognostic Value of Pretreatment Modified Glasgow Prognostic Score in Nivolumab-Treated Advanced Non-Small Cell Lung Cancer
Background/Objectives: Immune checkpoint inhibitors have become a standard treatment option for advanced/metastatic non-small cell lung cancer (NSCLC); however, considerable heterogeneity exists among patients regarding treatment response and survival. This study aimed to determine whether the pretreatment modified Gla...
Sedat Biter, Mehmet Mutlu Kıdı, Yasemin Aydınalp Camadan et al.
· Journal of Clinical Medicine · 0 citations